ReviewDrugs1997
Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.
Review in Drugs, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 138 citations in OpenAlex.
- CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.European journal of clinical pharmacology · 2012Trial
- Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2002Trial
- High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-II Receptor Blockers (ARBs) Initiators.Pharmacotherapy · 2025Article
- Albendazole Detection at a Nanomolar Level Through a Fabry-Pérot Interferometer Realized via Molecularly Imprinted Polymers.Sensors (Basel, Switzerland) · 2025Article
- A perspective on small molecules targeting the renin-angiotensin-aldosterone system and their utility in cardiovascular diseases: exploring the structural insights for rational drug discovery and development.RSC medicinal chemistry · 2025Review
- High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-II Receptor Blockers (ARBs) Initiators.medRxiv : the preprint server for health sciences · 2025Article
- Structure-property Relationships Reported for the New Drugs Approved in 2023.Mini reviews in medicinal chemistry · 2024Review
- Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.Archives of pharmacal research · 2023Article
- The NADPH Link between the Renin Angiotensin System and the Antioxidant Mechanisms in Dopaminergic Neurons.Antioxidants (Basel, Switzerland) · 2023Review
- Influence of AGTR1 and ABCB1 Gene Polymorphism on the Curative Effect of Irbesartan.International journal of hypertension · 2022Article
- From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?JHEP reports : innovation in hepatology · 2021Review
- Fabrication of electrospun nanofibres of BCS II drug for enhanced dissolution and permeation across skin.Journal of advanced research · 2016Article
- A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.Clinical pharmacokinetics · 2015Article
- Hepato-cardiac disorders.World journal of hepatology · 2014Review
- Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.Cardiovascular journal of Africa · 2013Article
- Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2013Article
- Liver abnormalities in cardiac diseases and heart failure.The International journal of angiology : official publication of the International College of Angiology, Inc · 2011Article
- 2-(4-Methyl-phen-yl)benzonitrile.Acta crystallographica. Section E, Structure reports online · 2011Article
- Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.Patient related outcome measures · 2011Article
- Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients.Journal of human hypertension · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII. In patients with mild to moderate hypertension, once daily administration of irbesartan 150 or 300 mg, with or without adjunctive antihypertensive agents, provides effective 24-hour BP control. Irbesartan reduced BP to a similar extent to enalapril and atenolol and to a significantly greater extent than losartan. The combination of irbesartan and hydrochlorothiazide resulted in additive antihypertensive effects. The drug is effective in the elderly and dosage adjustment is not required in these patients or in those with renal or hepatic failure. Preliminary studies evaluating the efficacy of irbesartan in patients with heart failure have produced encouraging results. Irbesartan is very well tolerated and neither the frequency nor the pattern of adverse events differed from those seen in placebo recipients, although headache was significantly more frequent with the latter. Similarly, the incidence of adverse events did not differ significantly between irbesartan and enalapril in patients who received either drug as monotherapy. Headache, upper-respiratory tract infection and musculoskeletal pain were the most common complaints. Thus, irbesartan is an effective therapy for patients with mild to moderate hypertension and had an adverse event profile similar to that of placebo in clinical trials. On this basis it would appear to be an effective therapeutic option in this indication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.